A new type of treatment, which combines a drug with gene therapy delivered directly into the brain, has been used for the first time in humans to treat epilepsy.
The clinical trial involved three adult men who had drug-resistant temporal lobe epilepsy associated with scarring in an area of the brain called the hippocampus. The approach used is known as chemogenetics, whereby a drug activates chemically engineered receptors introduced in the brain via gene therapy. This allows researchers to control the activity of cells in which these proteins are expressed. Chemogenetics is commonly used in research, but not as treatment in clinical practice.
'At the beginning, I think scientists like me felt like, why haven't we tried it in humans yet?', said Dr Minmin Luo from the Chinese Institute for Brain Research, Beijing, one of the senior authors of the study.
The research was published as a letter to the editor in The New England Journal of Medicine. The main aim was to assess the safety of the approach, and all reported adverse events were mild or moderate. However, the patients also experienced a mean 92.6 percent reduction in epileptic seizure frequency over the two-month assessment period and reported a better quality of life after the treatment.
The gene therapy was delivered directly to the hippocampus under the guidance of an MRI brain scan. It relied on a viral vector to insert a gene coding for specifically designed receptors in excitatory neurons whose abnormal activity leads to seizures in epilepsy. Two weeks after the procedure, the men began taking low doses of clozapine, an existing drug that activates these receptors. This, in turn, helped to suppress the electrical activity of the neurons.
The patients in the study had each been diagnosed with epilepsy for between ten and 25 years and had tried at least two different medications, which did not work. Approximately one in three people with epilepsy have a form of the disease which is resistant to currently available drugs.
'It's exciting that there's such a dramatic effect, and that they see very few side effects,' said Professor Matthew Walker from University College London, who was not involved in the research.
However, the study involved only three patients and did not include a control group. More research will be needed to provide further evidence of the treatment's safety and effectiveness.
Sources and References
-
Chemogenetic neuromodulation for refractory epilepsy
-
Epileptic seizures nearly vanish after people receive experimental gene therapy in their brains
-
Early gene therapy trial for drug-resistant epilepsy shows over 90 percent seizure reduction
-
Designer receptor therapy long used in the lab crosses over into humans
-
Experimental gene therapy on human brain reduces epileptic seizures by 90 percent

